DK513388A - Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2 - Google Patents

Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2

Info

Publication number
DK513388A
DK513388A DK513388A DK513388A DK513388A DK 513388 A DK513388 A DK 513388A DK 513388 A DK513388 A DK 513388A DK 513388 A DK513388 A DK 513388A DK 513388 A DK513388 A DK 513388A
Authority
DK
Denmark
Prior art keywords
peptides
hiv
viruses
init
antigen
Prior art date
Application number
DK513388A
Other languages
English (en)
Other versions
DK174705B1 (da
DK513388D0 (da
Inventor
Marc Alizon
Luc Montagnier
Denise Guetard
Francois Clavel
Pierre Sonigo
Mireille Guyader
Pierre Tiollais
Lisa Chakrabarti
Ronald Desrosiers
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27251436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK513388(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/003,764 external-priority patent/US5051496A/en
Priority claimed from FR8701739A external-priority patent/FR2610632B1/fr
Priority claimed from FR8705398A external-priority patent/FR2614025B1/fr
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of DK513388D0 publication Critical patent/DK513388D0/da
Publication of DK513388A publication Critical patent/DK513388A/da
Priority to DK200201277A priority Critical patent/DK175879B1/da
Application granted granted Critical
Publication of DK174705B1 publication Critical patent/DK174705B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
DK198805133A 1987-01-16 1988-09-15 Peptider med immunologiske egenskaber svarende til HIV-2 virus, antigene og immunogene midler indeholdende sådanne peptider samt fremgangsmåde og kit til en vitro diagnose af HIV-2 DK174705B1 (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK200201277A DK175879B1 (da) 1987-01-16 2002-08-30 Nucleotidsekvenser, der koder for peptider med immunologiske egenskaber og rekombinante nucleinsyrer omfattende nucleotidsekvenserne

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US07/003,764 US5051496A (en) 1986-01-22 1987-01-16 Peptides related to human immunodeficiency virus II (HIV-2)
US376487 1987-01-16
FR8701739A FR2610632B1 (fr) 1987-02-11 1987-02-11 Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
FR8705398A FR2614025B1 (fr) 1987-04-15 1987-04-15 Peptides susceptibles d'etre reconnus par des anticorps induits contre des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
FR8701739 1987-04-15
FR8705398 1987-04-15
FR8800025 1988-01-05
PCT/FR1988/000025 WO1988005440A1 (fr) 1987-01-16 1988-01-15 Peptides ayant des proprietes immunologiques 2-hiv-2

Publications (3)

Publication Number Publication Date
DK513388D0 DK513388D0 (da) 1988-09-15
DK513388A true DK513388A (da) 1988-11-16
DK174705B1 DK174705B1 (da) 2003-09-29

Family

ID=27251436

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198805133A DK174705B1 (da) 1987-01-16 1988-09-15 Peptider med immunologiske egenskaber svarende til HIV-2 virus, antigene og immunogene midler indeholdende sådanne peptider samt fremgangsmåde og kit til en vitro diagnose af HIV-2

Country Status (9)

Country Link
EP (1) EP0283327B1 (da)
JP (5) JP2948823B2 (da)
AT (1) ATE154808T1 (da)
AU (1) AU608294B2 (da)
DE (1) DE3855947T2 (da)
DK (1) DK174705B1 (da)
ES (1) ES2104556T3 (da)
GR (1) GR3024823T3 (da)
WO (1) WO1988005440A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701628D0 (sv) * 1987-04-16 1987-04-16 Erling Norrby Medel for analys mm
WO1989002277A2 (en) * 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0316695B1 (de) * 1987-11-16 1993-03-31 F. Hoffmann-La Roche Ag Rekombinante HIV-2 Polypeptide
US5780038A (en) * 1987-11-16 1998-07-14 Roche Diagnostic Systems, Inc. HIV-2 envelope polypeptides
EP0327801A1 (en) * 1988-01-08 1989-08-16 Deutsches Primatenzentrum Gesellschaft Mbh HIV-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
FR2632644B1 (fr) * 1988-06-10 1994-11-04 Pasteur Institut Antigenes precurseurs des glycoproteines d'enveloppe d'un retrovirus humain hiv-2 et antigenes presentant une parente immunologique avec ces derniers. preparation de ces antigenes. application au diagnostic
JP3093763B2 (ja) * 1988-06-09 2000-10-03 インスティチュート・パスツール ヒトレトロウィルスｈｉｖ―２の外被糖タンパク質の前駆抗原及びそれと免疫学的同族性をもつ抗原、ならびにこれらの抗原の調製方法及び診断への応用
DE68925660T2 (de) * 1988-06-10 1996-09-26 United Biomedical Inc Peptidfragmente von HIV
IL90553A0 (en) * 1988-06-13 1990-01-18 Us Health Protein and coding sequence for detection and differentiation of siv and hiv-2 group of viruses
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
EP0362927A3 (en) * 1988-10-06 1990-11-14 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv antibodies
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
US5260189A (en) * 1988-12-20 1993-11-09 Immunodiagnostics, Inc. Synthetic HIV-like peptides their compositions and uses
CA2032505C (fr) * 1989-05-12 2001-07-10 Ara Hovanessian Antigenes de la glycoproteine transmembranaire d'enveloppe d'un retrovirus humain du type hiv-2 antigenes presentant avec eux une parente immunologique
FR2646854A1 (fr) * 1989-05-12 1990-11-16 Pasteur Institut Antigenes de la glycoproteine transmembranaire d'enveloppe d'un retrovirus humain du type hiv-2 antigenes presentant avec eux une parente immunologique
DE68925202T2 (de) * 1989-05-31 1996-06-05 Pasteur Institut HIV-2-EHO-Retrovirus-Proteine und -Glycoproteine, Antikörper gegen sie, Verwendung für diagnostische Zwecke
FR2647809B1 (fr) * 1989-06-02 1991-09-20 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
US7022814B1 (en) 1992-01-21 2006-04-04 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
FR2647810B1 (fr) * 1989-06-02 1994-07-22 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
ES2262166T3 (es) * 1989-06-02 2006-11-16 Institut Pasteur Sintesis de proteinas o polipeptidos codificados por un secuencia nucleotidica vih-1, vih-2 o siv.
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
EP0438332B1 (fr) * 1990-01-16 1998-04-08 Orgenics Ltd. Peptides dérivant de la glycoprotéine d'enveloppe de virus HIV, leurs applications à la détection d'une infection due à ces virus et à la vaccination contre le SIDA
FR2657016B1 (fr) * 1990-01-16 1995-08-25 Clonatec Sa Peptides derivant de la glycoproteine d'enveloppe du virus-hiv-2, leurs applications a la detection d'une infection due a ce virus et a la vaccination contre le sida.
DE4002636A1 (de) * 1990-01-30 1991-08-01 Boehringer Mannheim Gmbh Expression von hiv1- und 2-polypeptiden und deren verwendung
WO1992021377A1 (en) * 1991-06-03 1992-12-10 Syntello Inc. Peptides for use in induction of t cell activation against hiv-1
JP3907201B2 (ja) 1991-12-23 2007-04-18 カイロン コーポレイション 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのｈｉｖプローブ
JPH0748276A (ja) * 1992-03-26 1995-02-21 Inmeru:Kk Ｈｉｖ感染症予防ワクチンおよびその製造法
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
EP1000177B1 (en) * 1997-08-01 2007-04-25 Genetic Systems Corporation Synthetic antigens for the detection of antibodies having immunoreactivity against hiv virus
DE19908766C2 (de) * 1999-02-19 2001-02-15 Ulrich Schubert Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien
WO2005097822A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
CA2577183C (en) * 2004-08-17 2014-02-18 Institut Gustave Roussy Mutated hiv nef for modulating immunity
WO2007084021A2 (en) * 2006-01-17 2007-07-26 Instituto De Medicina Molecular Compositions and methods for diagnosing hiv-2 infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387914B1 (en) * 1984-10-18 1993-08-04 Institut Pasteur Envelope antigens of the human immuno-deficiency virus, and their applications
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
NZ215867A (en) * 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
DE3533440A1 (de) * 1985-09-19 1987-03-26 Hoechst Ag N-substituierte 3,4,5,6-tetrahydrophthalimide, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
FR2593189B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
EP0239425B1 (fr) * 1986-01-22 1989-11-02 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le SIDA, et ses constituants antigéniques et nucléiques
EP0269520A3 (fr) * 1986-11-21 1988-08-24 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le sida, et ses constituants antigéniques et nucléiques
JP3105581B2 (ja) * 1991-07-03 2000-11-06 内橋エステック株式会社 面状温度ヒュ−ズ
JPH0833969A (ja) * 1994-07-22 1996-02-06 Toyota Motor Corp 加圧鋳造方法

Also Published As

Publication number Publication date
JPH11322792A (ja) 1999-11-24
DE3855947T2 (de) 1997-12-11
WO1988005440A1 (fr) 1988-07-28
JP2862810B2 (ja) 1999-03-03
GR3024823T3 (en) 1998-01-30
DK174705B1 (da) 2003-09-29
ES2104556T3 (es) 1997-10-16
JP2004002421A (ja) 2004-01-08
DK513388D0 (da) 1988-09-15
AU608294B2 (en) 1991-03-28
EP0283327A3 (fr) 1989-01-04
JP2002030099A (ja) 2002-01-29
JP2948823B2 (ja) 1999-09-13
EP0283327A2 (fr) 1988-09-21
JPH01502119A (ja) 1989-07-27
AU1225088A (en) 1988-08-10
DE3855947D1 (de) 1997-07-31
EP0283327B1 (fr) 1997-06-25
JPH07300498A (ja) 1995-11-14
ATE154808T1 (de) 1997-07-15

Similar Documents

Publication Publication Date Title
DK513388D0 (da) Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
ES2061500T5 (es) Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
KR950032278A (ko) 사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도
ES2004133A6 (es) Procedimiento para la preparacion de una nueva proteina.
ES2013346A6 (es) Metodos para producir secuencias y moleculas de adn recombinante, asi como proteinas t4 solubles.
DK637988D0 (da) Rekombinante polypeptider
DK373489D0 (da) Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler
EP0293792A3 (en) Human immunodeficiency virus gag-encoded proteins
EP0250128A3 (en) Novel virus isolated from patients with aids
DK284389A (da) Precursorantigener
ATE417108T1 (de) Hiv-2 und siv-1 nukleotidsequenzen
PT86752A (pt) Procede pour la preparation de peptides susceptibles d:etre reconnus par des anticorps induits contre des retrovirus d:immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et le cas echeant a la vaccination contre le sida

Legal Events

Date Code Title Description
PUP Patent expired